ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by FarmerBettyon May 16, 2023 5:17pm

237 Views

Post# 35451180

SEC Filings

Yes in sec filings the company comments obtained FDA clearance for PMN 310 on May 5th. The company is planning a phase 1a clinical trial of PMN 310, subject to sufficient available resources.

Would not think it would be difficult to get 8 healthy folks started, but these delays are for a reason not cash, it's PARTNER time.

They don't really have any other work going on with ALS and PD programs at a stand sill. They spent 150K on other platforms last qtr which is peanuts.

<< Previous

Bullboard Posts

Next >>

Consumer advocacy law firm investigates Microsoft over X-Box data concerns